These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Assessment of Simplified Methods for Quantification of Kramer GM; Yaqub M; Vargas HA; Schuit RC; Windhorst AD; van den Eertwegh AJM; van der Veldt AAM; Bergman AM; Burnazi EM; Lewis JS; Chua S; Staton KD; Beattie BJ; Humm JL; Davis ID; Weickhardt AJ; Scott AM; Morris MJ; Hoekstra OS; Lammertsma AA J Nucl Med; 2019 Sep; 60(9):1221-1227. PubMed ID: 30850488 [No Abstract] [Full Text] [Related]
6. Quantification of 18F-fluorocholine kinetics in patients with prostate cancer. Verwer EE; Oprea-Lager DE; van den Eertwegh AJ; van Moorselaar RJ; Windhorst AD; Schwarte LA; Hendrikse NH; Schuit RC; Hoekstra OS; Lammertsma AA; Boellaard R J Nucl Med; 2015 Mar; 56(3):365-71. PubMed ID: 25678491 [TBL] [Abstract][Full Text] [Related]
7. Relationship between Biodistribution and Tracer Kinetics of van de Stadt EA; Yaqub M; Schuit RC; Bartelink IH; Leeuwerik AF; Schwarte LA; de Langen AJ; Hendrikse H; Bahce I Diagnostics (Basel); 2022 Apr; 12(4):. PubMed ID: 35453931 [TBL] [Abstract][Full Text] [Related]
8. Simplified Methods for Quantification of Jansen BHE; Yaqub M; Voortman J; Cysouw MCF; Windhorst AD; Schuit RC; Kramer GM; van den Eertwegh AJM; Schwarte LA; Hendrikse NH; Vis AN; van Moorselaar RJA; Hoekstra OS; Boellaard R; Oprea-Lager DE J Nucl Med; 2019 Dec; 60(12):1730-1735. PubMed ID: 31000583 [TBL] [Abstract][Full Text] [Related]
13. Development of [18F]afatinib as new TKI-PET tracer for EGFR positive tumors. Slobbe P; Windhorst AD; Stigter-van Walsum M; Schuit RC; Smit EF; Niessen HG; Solca F; Stehle G; van Dongen GA; Poot AJ Nucl Med Biol; 2014 Oct; 41(9):749-57. PubMed ID: 25066021 [TBL] [Abstract][Full Text] [Related]
14. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer. Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221 [TBL] [Abstract][Full Text] [Related]
15. Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients. Bartelink IH; van de Stadt EA; Leeuwerik AF; Thijssen VLJL; Hupsel JRI; van den Nieuwendijk JF; Bahce I; Yaqub M; Hendrikse NH Pharmaceuticals (Basel); 2022 Jun; 15(7):. PubMed ID: 35890095 [TBL] [Abstract][Full Text] [Related]
16. A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice. Slobbe P; Windhorst AD; Stigter-van Walsum M; Smit EF; Niessen HG; Solca F; Stehle G; van Dongen GA; Poot AJ EJNMMI Res; 2015; 5():14. PubMed ID: 25853020 [TBL] [Abstract][Full Text] [Related]
17. Quantitative parametric perfusion images using 15O-labeled water and a clinical PET/CT scanner: test-retest variability in lung cancer. van der Veldt AA; Hendrikse NH; Harms HJ; Comans EF; Postmus PE; Smit EF; Lammertsma AA; Lubberink M J Nucl Med; 2010 Nov; 51(11):1684-90. PubMed ID: 20956480 [TBL] [Abstract][Full Text] [Related]